Document Detail


Rilmenidine--its antihypertensive efficacy, safety and impact on quality of life in perimenopausal women with mild to moderate essential hypertension.
MedLine Citation:
PMID:  16492616     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: A prospective, open-labeled study to assess the antihypertensive effect of monotherapy with rilmenidine and its impact on quality of life (QoL), as well as on biochemical parameters in perimenopausal women with essential hypertension. DESIGN AND METHODS: Fifty-five perimenopausal women with mild to moderate essential hypertension (mean age 51.4+/-2.4 years) were enrolled. At baseline and after 12-week monotherapy with rilmenidine, we assessed: systolic (SBP) and diastolic (DBP) blood pressure (BP), heart rate (HR), fasting glucose, serum creatinine and total cholesterol levels. QoL was also assessed at baseline and at 12 weeks by two standardized questionnaires: the Short Form - 36 (SF-36) and the Subjective Symptoms Assessment Profile (SSAP). Statistical analysis was performed using Student's t-test to compare changes in BP, QoL and biochemical parameters during therapy with rilmenidine. RESULTS: After 12 weeks of therapy, there was a significant decrease in BP and HR. Normalization of BP was observed in 46 (84%) women. Rilmenidine did not influence serum creatinine, fasting glucose and lipid profile. Treatment was very well tolerated by the patients and no side-effects were noted. Both the SF-36 and the SSAP demonstrated improvement in general QoL. We observed a significant improvement in all SF-36 subscales. In the SSAP, a similar significant improvement was found, except dizziness subscale. Improvement in QoL was not related to reduction of BP. CONCLUSIONS: Monotherapy with rilmenidine is safe and effective in BP treatment and significantly improves QoL in perimenopausal women with essential hypertension.
Authors:
Kalina Kawecka-Jaszcz; Danuta Czarnecka; Marek Klocek; Michał Zabojszcz; Marta Kucharska; Rafał Jaworski; Robert Pachocki
Related Documents :
11319676 - Treating hypertension with a device that slows and regularises breathing: a randomised,...
19550356 - Superior consistency of ambulatory blood pressure monitoring in children: implications ...
9270086 - Rest and effort hemodynamic responses during prolonged treatment with felodipine, 24-h ...
9285106 - Treatment situation of hypertensive patients in finnish primary health care.
9519216 - Diaphragm shortening and intrathoracic pressure during hypercapnia in rats.
8197316 - Parental history of hypertension, menstrual cycle phase, and cardiovascular response to...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood pressure     Volume:  15     ISSN:  0803-7051     ISO Abbreviation:  Blood Press.     Publication Date:  2006  
Date Detail:
Created Date:  2006-02-22     Completed Date:  2006-06-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9301454     Medline TA:  Blood Press     Country:  Norway    
Other Details:
Languages:  eng     Pagination:  51-8     Citation Subset:  IM    
Affiliation:
Ist Cardiac Department, Medical College Jagiellonian University, Cracow, Poland. mckaweck@cyf-kr.edu.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / adverse effects,  pharmacology*
Blood Pressure / drug effects*
Female
Heart Rate / drug effects*
Humans
Hypertension / blood,  drug therapy*,  physiopathology
Middle Aged
Oxazoles / adverse effects,  pharmacology*
Perimenopause* / blood
Prospective Studies
Quality of Life
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Oxazoles; 54187-04-1/rilmenidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of an estrogen receptor-alpha gene polymorphism with left ventricular mass.
Next Document:  Health behavior change models and theories: contributions to rehabilitation.